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Changes in US Lifetime Heroin Use and Heroin Use Disorder
Prevalence From the 2001-2002 to 2012-2013 National
Epidemiologic Survey on Alcohol and Related Conditions
Silvia S. Martins, MD, PhD; Aaron Sarvet, MPH; Julian Santaella-Tenorio, MSc; Tulshi Saha, PhD;
Bridget F. Grant, PhD; Deborah S. Hasin, PhD
IMPORTANCE Heroin use is an urgent concern in the United States. Little is know about the
course of heroin use, heroin use disorder, and associated factors.
OBJECTIVE To examine changes in the lifetime prevalence, patterns, and associated
demographics of heroin use and use disorder from 2001-2002 to 2012-2013 in 2 nationally
representative samples of the US adult general population.
DESIGN, SETTING, AND PARTICIPANTS This survey study included data from43093
respondents of the 2001-2002 National Epidemiologic Survey on Alcohol and Related
Conditions (NESARC) and 36 309 respondents of the 2012-2013 NESARC-III. Data were
analyzed from February 2 to September 15, 2016.
MAIN OUTCOMES ANDMEASURES Lifetime heroin use andDSM-IV heroin use disorder.
RESULTS Among the 79 402 respondents (43.3%men; 56.7%women; mean [SD] age,
46.1 [17.9] years), prevalence of heroin use and heroin use disorder significantly increased
from 2001-2002 to 2012-2013 (use: 0.33% [SE, 0.03%] vs 1.6% [SE, 0.08%]; disorder:
0.21% [SE, 0.03%] vs 0.69% [SE, 0.06%]; P < .001). The increase in the prevalence of heroin
use was significantly pronounced among white (0.34% [SE, 0.04%] in 2001-2002 vs 1.90%
[SE, 0.12%] in 2012-2013) compared with nonwhite (0.32% [SE, 0.05%] in 2001-2002 vs
1.05% [SE, 0.10%] in 2012-2013; P < .001) individuals. The increase in the prevalence of
heroin use disorder was more pronounced among white individuals (0.19% [SE, 0.03%] in
2001-2002 vs 0.82% [SE, 0.08%] in 2012-2013; P < .001) and those aged 18 to 29 (0.21%
[SE, 0.06%] in 2001-2002 vs 1.0% [0.17%] in 2012-2013; P = .01) and 30 to 44 (0.20% [SE,
0.04%] in 2001-2002 vs 0.77% [0.10%] in 2012-2013; P = .03) years than among nonwhite
individuals (0.25% [SE, 0.04%] in 2001-2002 vs 0.43% [0.07%] in 2012-2013) and older
adults (0.22% [SE, 0.04%] in 2001-2002 vs 0.51% [SE, 0.07%] in 2012-2013). Among users,
significant differences were found across time in the proportion of respondents meeting
DSM-IV heroin use disorder criteria (63.35% [SE, 4.79%] in 2001-2001 vs 42.69% [SE,
2.87%] in 2012-2013; P < .001). DSM-IV heroin abuse was significantly more prevalent among
users in 2001-2002 (37.02% [SE, 4.67%]) than in 2012-2013 (19.19% [SE, 2.34%]; P = .001).
DSM-IV heroin dependence among users was similar in 2001-2002 (28.22% [SE, 3.95%]) and
in 2012-2013 (25.02% [SE, 2.20%]; P = .48). The proportion of those reporting initiation of
nonmedical use of prescription opioids before initiating heroin use increased across time
among white individuals (35.83% [SE, 6.03%] in 2001-2002 to 52.83% [SE, 2.88%] in
2012-2013; P = .01).
CONCLUSIONS AND RELEVANCE The prevalence of heroin use and heroin use disorder
increased significantly, with greater increases among white individuals. The nonmedical use
of prescription opioids preceding heroin use increased among white individuals, supporting
a link between the prescription opioid epidemic and heroin use in this population. Findings
highlight the need for educational campaigns regarding harms related to heroin use and the
need to expand access to treatment in populations at increased risk for heroin use and heroin
use disorder.
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H eroin is anurgent concern in theUnitedStates.1,2Risksassociated with heroin use and addiction includemortality,3,4 overdose,1,5,6 infectious diseases,1,7 and
impaired psychological status and social relationships.8 In-
creases in serious consequences of heroin use, including
overdoses,9 emergency department visits,10 and public drug
abuse treatment,11 have led to widespread concerns about a
heroin epidemic.6 Although studies have addressed the link
between use of prescription opioids (POs) and heroin,1,2,12-15
most information on trends in US adult heroin use is indirect,
obtained through studies of its sequelae.10,11
Studies of trends in the consequences of heroin use, such
asoverdoses,are important.However, thesestudiesdonotpro-
vide information about underlying trends in the population
burdens of heroin use and related disorders in US adults or in
thecharacteristics andpatternsofuseamongheroinusers. For
suchtrends,national surveydataareneeded.TheNationalSur-
vey on Drug Use and Health (NSDUH) is a potential source of
such information.However, other thanbrief summaries,1,16,17
little has beenpublished fromNSDUHon trends inheroinuse.
Apart from the NSDUH, no studies known to us have ad-
dressed time trends in heroin consumption among US repre-
sentative samples, including change over time in the preva-
lence of lifetime heroin use and heroin use disorders overall
or patterns and characteristics of heroin use and related dis-
orders among users (eg, age at onset, use frequency, disorder
severity, types of abuse, or dependence symptoms en-
dorsed). Using US adult national surveys conducted during
2001-2002 and 2012-2013, we addressed the following ques-
tions. First, did prevalence of lifetime heroin use and related
disorders increase? Second, did demographic characteristics
associated with lifetime heroin use and heroin use disorders
change? Third, did patterns, severity, and substance comor-
bidity of heroin use and related disorders change?
Methods
Study Design and Participants
Weobtained data from the following 2 nationally representa-
tive face-to-facehouseholdsurveysofadults 18yearsandolder
residing in households and group quarters18,19: the 2001-
2002 National Epidemiologic Survey on Alcohol and Related
Conditions (NESARC) (n = 43093), andthe2012-2013NESARC-
III (n = 36 309). NESARC and NESARC-III used similar multi-
stageprobability samplingdesignswithoversampling forHis-
panic, black, and (inNESARC-III)Asian individuals.19-21 Survey
weightswereused toadjust fordifferential probabilitiesofpar-
ticipant selection and household and person-level nonre-
sponse and adjusted sample margins to match key demo-
graphic distributions (eg, age, sex, and race) of each target
population.19,22 NESARC and NESARC-III used computer-
assisted interviews and highly trained interviewers. Re-
sponse rates inNESARC (60.1%) andNESARC-III (81.0%)were
comparable to those of other national surveys.23,24 Inter-
viewer quality assurance methods were similar across
surveys.22 The US Census Bureau and US Office of Manage-
ment and Budget conducted a full ethical review and ap-
proved all protocols and study consent procedures for 2001-
2002NESARC.The2012-2013NESARC-III protocols andstudy
consent procedures were approved by the institutional re-
view boards of Westat and the National Institutes of Health.
Respondents gave written informed consent and were com-
pensated for participation.
Assessments
Heroin Use andDSM-IVUse Disorder
The National Institute on Alcohol Abuse and Alcoholism Al-
coholUseDisorderandAssociatedDisabilities InterviewSched-
ule IV (AUDADIS-IV), a fully structured diagnostic interview
designed for use by nonclinician interviewers after struc-
tured training, was used to assess substance use and psychi-
atricdisorders according toDSM-IV criteria. InNESARC-III, the
AUDADIS-5wasusedtoassess substanceuseandDSM-IV25and
DSM-526 criteria for substance use disorders.
Lifetime heroin use (ever vs never used heroin) wasmea-
sured in both surveys andwas included as a binary (yes or no)
variable in our analyses. The reliability and validity of AU-
DADIS DSM-IV substance use disorder diagnoses have been
well documented.27-40 We combined abuse and dependence
because the criteria reflect a single disorder rather than 2
conditions.41 Symptom items (n = 30) that assessed DSM-IV
heroin use disorder (abuse and dependence) in the NESARC
andNESARC-IIIwerevirtually identical.However,4 itemswere
slightly reworded and 1 abuse item appeared in the NESARC
but not the NESARC-III, whereas a different abuse item ap-
peared in the NESARC-III but not the NESARC. Comparisons
betweenDSM-IVheroinusedisorderdiagnoseswithandwith-
out the additional questions yieldedvirtually identical preva-
lences (NESARC: 0.69% vs 0.68%; NESARC-III: 0.21% vs
0.21%), with corresponding near perfect or perfect concor-
dance (κ = 0.998 and κ = 1.00, respectively), suggesting that
these trivial differences could not account for the substantial
differences in prevalence between the surveys.
Patterns of Heroin Use
Variables includedageat firstuse,periodofuse (before thepast
12months only, past 12months only, or both periods) and fre-
quency of use during the heaviest-use period (every day or
Key Points
Question Did a change occur in the prevalence, course, and
associated demographics of heroin use and heroin use disorder
from 2001-2002 to 2012-2013?
Findings In this population-based survey study of 79 402
respondents, the prevalence of heroin use (1.61% vs 0.33%) and
related disorder (0.69% vs 0.21%) was significantly higher in
2012-2013 than in 2001-2002, with greater increases among
white individuals. The proportion of individuals reporting initiation
of nonmedical use of prescription opioids before heroin use
increased across time among white users only.
Meaning The use of prescription opioids may have contributed to
the greater increase in the prevalence of heroin use and related
disorder observed among white individuals.
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nearly every day or other). Heroin use disorder included use
disorder overall, abuse, dependence, the abuse and depen-
dence criteria, driving under the influence of heroin, and
the number of lifetime heroin disorder criteria (0-1, 2-3, 4-5,
and ≥6).
Other Substance Use
Lifetime use of other substances (sedatives or tranquilizers,
stimulants,marijuana, cocaineor crack, hallucinogens, inhal-
ants, POs, and other substances) on one’s own was included
andmeasured identically across surveys. BecausePOuse is of
special interest,we createdavariable indicatingwhethernon-
medical PO (NMPO) use among heroin userswas initiated be-
fore heroin use.
Demographic Data
Demographic characteristics,measured identically across sur-
veys, included sex (male or female), age (18-29, 30-44, or ≥45
years), educational level (less than high school, high school,
or some college ormore), race/ethnicity (non-Hispanic white
vs nonwhite [non-Hispanic black, Hispanic, Asian or Pacific
Islander, or Native American]), marital status (unmarried;
married or living as married; or widowed, separated, or di-
vorced), urbanicity (inmetropolitan statistical areas or other),
region (Northeast, Midwest, South, orWest, coded according
to US Census definitions based on the location of partici-
pants’ residences), and federal poverty level (<100% [below
poverty level], 100%-200%,and>200%).Federalpoverty level
wasdeterminedby family incomeandsize andby federal pov-
erty guidelines.42
Statistical Analysis
Data were analyzed from February 2 to September 15, 2016.
We combined NESARC and NESARC-III data to conduct re-
peated cross-sectional analyses, aswasdonepreviously to ex-
amine other trends in these surveys.22,43,44 We added a vari-




els for each heroin outcome (lifetime use or lifetime use dis-
order) to estimatewhether prevalences differedbetween sur-
veys,wemodeled surveyyear as associatedwith theoutcome.




veys, we added an interaction term between the survey year
and each demographic variable to all models. To assess dif-
ferential associations on the prevalence scale, we first esti-
mated prevalence differences between strata of the demo-
graphic variables (eg, male and female respondents) within
each survey.We testedwhether these prevalence differences
differed between surveys (eg, male and female respondents
in NESARC vs male and female respondents in NESARC-III)
using pairwise t tests for independent samples.We estimated
these prevalences and their SEs from model-predicted log-
odds, back-transformed to the prevalence scale.45
Third, we estimated the distributions of variables corre-
sponding to various aspects of severity andpatterns of heroin
use among heroin users in each survey. To testwhether these
distributions differed significantly between survey years, we
usedWald χ2 tests (categorical variables) orWaldF tests (con-
tinuousvariables),withP < .05 indicatingsignificance.Weused
SUDAANsoftware (version 11.0.1)46 to incorporate theweights
and complex design features of the surveys. Unless other-
wise indicated, data are expressed as prevalence (SE).
Results
Lifetime Heroin Use, Heroin Use Disorder,
and Demographic Characteristics
The sample included 79402 respondents (43.3%men; 56.7%
women; mean [SD] age, 46.1 [17.9] years) of the NESARC and
NESARC-III. Lifetimeprevalenceofheroinuse increased from
2001-2002 (0.33%[0.03%]) to2012-2013 (1.61%[0.08%])over-
all and among all subgroups: 18 to 29 years of age (0.26%
[0.07%] to 1.81%[0.21%];P = .09), 30 to44yearsof age (0.36%
[0.06%] to 1.75%[0.17%];P = .21), and45yearsorolder (0.35%
[0.05%] to 1.46% [0.11%]). Past-year prevalence of heroin use
also increased from 2001-2002 (0.03% [0.01%) to 2012-2013
(0.21% [0.03%]; P < .001).
Lifetime prevalence of heroin use disorder increased sig-
nificantly from 2001-2002 (0.21% [0.03%]) to 2012-2013
(0.69% [0.06%]) overall and among all subgroups: 18 to 29
years of age (0.21% [0.06%] to 1.01% [0.17%]; P = .01), 30 to
44yearsof age (0.20%[0.04%] to0.77%[0.10%];P = .03), and
45 years or older (0.22% [0.04%] to 0.51% [0.07%]). In-
creases in use anduse disorder remained significant between
surveyswhenadjustedby lifetimeNMPO.Amongmen,preva-
lence of heroin use (0.52% [0.05%] to 2.41% [0.15%]) and use
disorder (0.32%[0.04%] to 1.04%[0.11%]) increasedmore than
among women (0.16% [0.03%] to 0.86% [0.07%] and 0.11%
[0.03%] to 0.36% [0.40%], respectively; P < .001). In 2001-
2002, white and nonwhite individuals had similar preva-
lences of heroin use (0.34% [0.04%] and 0.32% [0.05%], re-
spectively); in 2012-2013, heroin usewas significantly higher
amongwhite (1.90% [0.12%]) than nonwhite (1.05% [0.10%];
P < .001) individuals. Heroin use and use disorder increased
more among previously married (0.48% [0.08%] to 2.33%
[0.19%]; P < .001; and 0.30% [0.06%] to 0.88% [0.10%];
P = .01; respectively) andunmarried (0.51% [0.09%] to 2.29%
[0.21%]and0.38%[0.08%]to1.30%[0.17%], respectively) than
amongmarried (0.23%[0.04%] to 1.10%[0.10%];P < .001; and
0.13% [0.03%] to 0.38% [0.06%]; P = .002 respectively) re-
spondents. Similar findingswere observed among thosewith
educational levels of less than high school (0.41% [0.09%] to
2.01% [0.23%];P = .03; and0.24% [0.07%] to0.87% [0.16%];
P = .08; respectively) and no more than high school (0.39%
[0.07%] to2.15%[0.19%];P = .003;and0.29%[0.06%] to1.11%
[0.14%]; P = .003; respectively) comparedwith thosewho at-
tained higher educational levels (0.28% [0.04%] to 1.30%
[0.10%] and 0.16% [0.03%] to 0.47% [0.06%], respectively).
Forheroinuseonly, prevalence significantly increasedamong
respondents at less than 100% of the federal poverty level
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(0.44% [0.11%] to 2.42% [0.22%];P < .001) and those at 100%
to200%of thepoverty level (0.42%[0.08%] to 1.95%[0.18%];
P = .008) comparedwith thosenot inpoverty (0.28% [0.03%]
to 1.22% [0.10%]) (Figure 1,Table 1,Table 2, and eTables 1 and
2 in the Supplement).
Lifetime Heroin Use Disorders and Heroin Use Patterns
Among Lifetime Users
Lifetime prevalence of heroin use disorder among users de-
creasedsignificantly from2001-2002(63.35%[4.79%]) to2012-
2013 (42.69% [2.87%]; P < .001). Although the prevalence of
dependenceandmostof its criteriawerestableacrossbothsur-
veys, DSM-IV heroin abuse was significantly less prevalent
among users in 2012-2013 (19.19% [2.34%]) than in 2001-
2002 (37.02% [4.67%]; P = .001), as were all 4 DSM-IV abuse
criteria. These included role failure (21.40%[1.86%]vs43.03%
[4.89%]; P < .001), physically hazardous use (31.79% [2.54%]
vs 47.46% [4.60%]; P = .005), legal problems (12.99% [1.91%]
vs 23.58% [4.02%]; P = .02), and use persistence despite re-
current social problems (30.92% [2.50%] vs 52.10% [5.03%];
P < .001) (Figure 2 and Table 3).
The proportion of heroin users who reported no history
of any other drug use increased between surveys (0 in 2001-
2002 vs 2.10% [0.66%] in 2012-2013; P = .003) (Table 3). The
proportion of those who ever drove under the influence of
heroindecreasedbetweensurveys (42.07%[4.69%]vs28.90%
[2.18%]; P = .01). The proportion of individuals experiencing
remission in heroin use and use disorder was similar in the
2001-2002 and 2012-2013 surveys (use, 90.73% [3.46%] vs
86.17% [2.18%]; P = .52; disorder, 88.86% [5.20%] vs 83.02%
[3.38%];P = .47). Frequency ofNMPOuse among individuals
who used heroin and POs in their lifetime did not differ be-
tween surveys. In race-stratified analyses, white individuals
were more likely to have initiated NMPO use before heroin
(35.83% [6.03%] in 2001-2002 and 52.83% [2.88] in 2012-
2013; P = .01), whereas nonwhite individuals were less likely
to have initiated NMPO use before heroin (44.12% [7.60%] in
2001-2002 and 26.20% [3.95%] in 2012-2013; P = .04). A
Figure 1. Lifetime Heroin Use in the 2001-2002National Epidemiologic Survey on Alcohol
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Differences in prevalences across
variable categories in NESARC are
compared with differences in
prevalences in NESARC-III.
FPL indicates federal poverty level.
Error bars indicate 95% CIs.
a P < .001, compared with women.
bP < .001, compared with nonwhite.
c P < .001, compared with married or
living as married.
dP = .03, compared with some
college or more.
e P = .003, compared with some
college or more.
f P < .001, compared with greater
than 200% FPL.
g P = .008, compared with greater
than 200% FPL.
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greater proportion of heroin users usedheroinmore than 100
times in2001-2002(51.12%[5.00%]) than in2012-2013 (43.73%
[2.45%]; P < .001).
Discussion
In the2012-2013NESARC-III, 1.61%ofUSadults hadeverused
heroin, and 0.69% had ever met criteria for a heroin use dis-
order. Extrapolation from these results indicates that in 2012-
2013, approximately 3800000USadults usedheroin at some
point in their lifetime and approximately 1 615000 US adults
evermet criteria for lifetimeheroinusedisorder. Between the
2001-2002NESARCand the2012-2013NESARC-III, thepreva-
lence of lifetime heroin use increased almost 5-fold and the
prevalence of lifetime heroin use disorder increased approxi-
mately3-fold.The increase in theprevalenceof lifetimeheroin
use disorder represented approximately 1 127000 additional
individuals with heroin use disorder in 2012 relative to 2001.
Despite the decreased risk for heroin use disorder among us-
ers, the large increase inusers led toanoverall increasedpreva-
lence of heroin use disorder in the adult population.
The increases thatwe show in lifetimeheroinuse anduse
disorder are consistent with increases in heroin outcomes in
several other studies during the same period. The NSDUH
showed a 62.5% increase in the rates of heroin use and a 90%
increase (from 1.0 to 1.9 per 1000 population) in the rates of
past-year heroin use disorder.17 In addition, mortality associ-
atedwith heroin overdoses increased 47 by 26% from2000 to
2013-2014.48Data fromtheTreatmentEpisodeDataSets show
an increase in admissions due to heroin as the primary drug
from15% in2003 to 19% in2013.11 Our studyexpandsonprior
investigations by presenting change over time in the US na-
tionalprevalenceof lifetimeheroinuseandusedisordersover-
all and amongusers by investigating patterns of use and char-
acteristics associated with heroin use and related disorders.
Table 1. Heroin Use and Demographic Correlates in the 2001-2002NESARC and the 2012-2013 NESARC-III
Variable
Unadjusted Lifetime Heroin Use
2001-2002 NESARC
(n = 43 093)
2012-2013 NESARC-III
(n = 36 309)
P Valuea
Prevalence
(SE), % PD (SE), %
Prevalence
(SE), % PD (SE), %
Overall 0.33 (0.03) NA 1.61 (0.08) NA NA
Sex
Male 0.52 (0.05) 0.36 (0.06) 2.41 (0.15) 1.55 (0.17) <.001
Female 0.16 (0.03) 1 [Reference] 0.86 (0.07) 1 [Reference] 1 [Reference]
Race/ethnicity
Non-Hispanic white 0.34 (0.04) 0.02 (0.06) 1.90 (0.12) 0.85 (0.17) <.001
Nonwhiteb 0.32 (0.05) 1 [Reference] 1.05 (0.10) 1 [Reference] 1 [Reference]
Age, y
18-29 0.26 (0.07) −0.09 (0.08) 1.81 (0.21) 0.35 (0.24) .09
30-44 0.36 (0.06) 0.01 (0.08) 1.75 (0.17) 0.29 (0.21) .21
≥45 0.35 (0.05) 1 [Reference] 1.46 (0.11) 1 [Reference] 1 [Reference]
Marital status
Married or living as married 0.23 (0.04) 1 [Reference] 1.10 (0.10) 1 [Reference] 1 [Reference]
Widowed, separated, or
divorced
0.48 (0.08) 0.25 (0.09) 2.33 (0.19) 1.23 (0.22) <.001
Unmarried 0.51 (0.09) 0.28 (0.10) 2.29 (0.21) 1.19 (0.25) <.001
Educational level
Less than high school 0.41 (0.09) 0.12 (0.10) 2.01 (0.23) 0.71 (0.25) .03
High school 0.39 (0.07) 0.11 (0.08) 2.15 (0.19) 0.85 (0.23) .003
Some college or more 0.28 (0.04) 1 [Reference] 1.30 (0.10) 1 [Reference] 1 [Reference]
Poverty levelc
<100% FPL 0.44 (0.11) 0.16 (0.12) 2.42 (0.22) 1.20 (0.26) <.001
100%-200% FPL 0.42 (0.08) 0.14 (0.09) 1.95 (0.18) 0.74 (0.20) .008
>200% FPL 0.28 (0.03) 1 [Reference] 1.22 (0.10) 1 [Reference] 1 [Reference]
Urbanicity
Rural 0.23 (0.07) 1 [Reference] 1.28 (0.18) 1 [Reference] 1 [Reference]
Urban 0.36 (0.04) 0.12 (0.08) 1.70 (0.09) 0.42 (0.20) .17
Region
Northeast 0.38 (0.09) 1 [Reference] 1.54 (0.21) 1 [Reference] 1 [Reference]
Midwest 0.22 (0.05) −0.16 (0.10) 1.54 (0.19) 0 (0.28) .59
South 0.32 (0.05) −0.06 (0.10) 1.60 (0.13) 0.06 (0.24) .66
West 0.42 (0.07) 0.05 (0.11) 1.74 (0.14) 0.21 (0.25) .57
Abbreviations: FPL, federal poverty
level; NA, not applicable;
NESARC, National Epidemiologic
Survey on Alcohol and Related
Conditions; PD, prevalence
difference.




black, Hispanic, Asian or Pacific
Islanders, or Native American.
c Determined by family income and
family size using the federal poverty
guidelines published annually by the
US Department of Health and
Human Services. Individuals or
families making less than 100% of
the FPL are considered to be below
the poverty level.
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Increases inheroinuseand relateddisorderswereparticu-
larly prominent among white individuals, leading to a signifi-
cantracegapinlifetimeheroinuseby2012-2013,consistentwith
other sources.17,49-51 In 2001-2002, only approximately one-
thirdofwhiteheroinusers reportedNMPOusebefore firstusing
heroin, whereas in 2012-2013, more than half of white heroin
users reported using NMPO before heroin. In contrast, fewer
nonwhite users reported using POs before heroin in the 2012-
2013 than in2001-2002periods.Thisdemographic shift is par-
allel to increases in NMPOs use since 2002, which has oc-
curred disproportionally among white individuals2,49-51 and
could be attributed to the disparities in prescribing opioids to
white patients, as shown in ameta-analysis.52 Increased avail-
ability and lower heroin prices in recent years may have con-
tributed to increased heroin use.17,49,53,54 In the past decade,
NMPO users have been at higher risk than nonusers for initia-
tion of heroin use.51,55-57 We explored the association of life-
time heaviest frequency of NMPO use with the risk for heroin
use in both surveys. Not surprisingly, the risk increased as fre-
quency of NMPO use increased. However, the increase in the
prevalenceofheroinuseoccurredacrossNMPOuse frequency
categories in NESARC-III compared with NESARC, suggesting
that factors other than increasingly frequent NMPO use con-
tributed to the increase in heroin use in adults in the 2012-
2013period.Differential increases in lifetimeheroinuseamong
white adults persisted even after controlling for potential dif-
ferential increases in lifetimeNMPOuse.Heroinuseappears to
havebecomemoresociallyacceptableamongsuburbanandru-
ralwhite individuals, perhapsbecause its effects seemsosimi-
lar to thoseofwidelyavailablePOs.13All thesefactorscouldcon-
tribute to increased prevalence of heroin use and use disorder
amongwhite users.
Thesexgap in lifetimeheroinuseandusedisorderwidened
from the 2001-2002 to 2012-2013 periods; use amongmen in-
Table 2.DSM-IVHeroin Use Disorder and Demographic Correlates in the 2001-2002NESARC
and the 2012-2013 NESARC-III
Variable
Unadjusted Lifetime DSM-IV Heroin Use Disordera
2001-2002 NESARC
(n = 43 093)
2012-2013 NESARC-III
(n = 36 309)
P Valueb
Prevalence,
(SE), % PD (SE), %
Prevalence
(SE), % PD (SE), %
Overall 0.21 (0.03) NA 0.69 (0.06) NA NA
Sex
Male 0.32 (0.04) 0.21 (0.05) 1.04 (0.11) 0.68 (0.12) <.001
Female 0.11 (0.03) 1 [Reference] 0.36 (0.04) 1 [Reference] 1 [Reference]
Race
Non-Hispanic white 0.19 (0.03) −0.06 (0.05) 0.82 (0.08) 0.38 (0.11) <.001
Nonwhite 0.25 (0.04) 1 [Reference] 0.43 (0.07) 1 [Reference] 1 [Reference]
Age, y
18-29 0.21 (0.06) −0.01 (0.07) 1.01 (0.17) 0.49 (0.19) .01
30-44 0.20 (0.04) −0.02 (0.05) 0.77 (0.10) 0.25 (0.11) .03
≥45 0.22 (0.04) 1 [Reference] 0.51 (0.07) 1 [Reference] 1 [Reference]
Marital status
Married or living as married 0.13 (0.03) 1 [Reference] 0.38 (0.06) 1 [Reference] 1 [Reference]
Widowed, separated, or
divorced
0.30 (0.06) 0.18 (0.06) 0.88 (0.10) 0.50 (0.11) .01
Unmarried 0.38 (0.08) 0.25 (0.09) 1.30 (0.17) 0.92 (0.19) .002
Educational level
Less than high school 0.24 (0.07) 0.08 (0.07) 0.87 (0.16) 0.40 (0.16) .08
High school 0.29 (0.06) 0.12 (0.07) 1.11 (0.14) 0.64 (0.16) .003
Some college or more 0.16 (0.03) 1 [Reference] 0.47 (0.06) 1 [Reference] 1 [Reference]
Poverty levelc
<100% FPL 0.40 (0.11) 0.25 (0.11) 1.14 (0.16) 0.64 (0.17) .05
100%-200% FPL 0.26 (0.06) 0.11 (0.06) 0.79 (0.12) 0.29 (0.12) .19
>200% FPL 0.15 (0.03) 1 [Reference] 0.50 (0.06) 1 [Reference] 1 [Reference]
Urbanicity
Rural 0.13 (0.04) 1 [Reference] 0.53 (0.12) 1 [Reference] 1 [Reference]
Urban 0.23 (0.03) 0.11 (0.05) 0.73 (0.06) 0.19 (0.13) .53
Region
Northeast 0.25 (0.08) 1 [Reference] 0.77 (0.15) 1 [Reference] 1 [Reference]
Midwest 0.14 (0.04) −0.11 (0.09) 0.71 (0.13) −0.05 (0.20) .78
South 0.23 (0.04) −0.02 (0.09) 0.71 (0.09) −0.06 (0.18) .84
West 0.22 (0.05) −0.03 (0.09) 0.57 (0.11) −0.20 (0.19) .43
Abbreviations: FPL, federal poverty
level; NA, not applicable;
NESARC, National Epidemiologic
Survey on Alcohol and Related
Conditions; PD, prevalence
difference.
a DSM-IV heroin use disorder refers to
DSM-IV drug abuse or dependence.
bCalculated as the difference in PDs
(back-transformed from predicted
marginal log-odds).
c Determined by family income and
family size using the federal poverty
guidelines published annually by the
US Department of Health and
Human Services. Individuals or
families making <100% of the FPL
are considered to be below the
poverty level.
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creasedmorethanamongwomen.Similar resultswerereported
using NSDUHdata.16,57 Changes in the heroin sex gap are con-
sistentwiththoseformarijuana.58,59Changes inexposuretorisk
factors forheroinmayexplain thewideningheroin sexgap.For
example,menmayhavebeenmoreaffectedbyeconomicstress-
ors than women (eg, low manufacturing employment rates60
leading to greater increases inmale heroin use).
Although heroin use is now more widespread among in-
dividuals of all socioeconomic strata (Table 1 and eTable 1 in
the Supplement) and among thosewith stronger bonds to so-
cial institutions,61 relative increases inheroinuse andusedis-
orderacross timeweregreater among lesseducatedandpoorer
individuals. These trends are concerningbecause increases in
the prevalence of heroin use and use disorder have been oc-
curring among vulnerable individuals who have few re-
sources to overcome problems associated with use.62,63 No
differences in prevalence of heroin use were found by age.
However, in NESARC-III, the prevalence of heroin use disor-
ders was significantly higher among younger than older aged
(≥45 years) groups.
Theproportionofheroinuserswithalifetimeheroinusedis-
order decreased between the 2 surveys, primarily owing to
decreases inDSM-IV abuse criteria. Some subgroups of heroin
users (thosewithgreater resourcesand infrequentusers)might
be less likelytodevelopmilderabusesymptoms.However, if the
prevalenceofheroinuse continues to increase, thenumbersof
thosewith heroin use disorderswill likely increase aswell.
No NESARC participants and 2.1% of NESARC-III partici-
pants reported that heroin was the only illicit drug they had
used. Although this result may seem surprising, it is consis-
tentwith reports that some individuals transition fromuse of
POs toheroinwithnohistory of other druguse besides POs.49
Limitations and Strengths
NESARCandNESARC-III lackedbiological testingforsubstances
andexcludedhomelessand incarcerated individuals. Including
Figure 2.DSM-IVHeroin Use Disorder in the 2001-2002National Epidemiologic Survey on Alcohol
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Differences in prevalences across
variable categories in NESARC are
compared with differences in
prevalences in NESARC-III. Error bars
indicate 95% CIs.
a P < .001, compared with women.
bP < .001, compared with nonwhite.
c P = .01, compared with 45 years or
older.
dP = .03, compared with 45 years or
older.
e P = .01, compared with married or
living as married.
f P = .002, compared with married or
living as married.
g P = .003, compared with some
college or more.
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Table 3. Patterns of Heroin Use Among Lifetime Heroin Users in the the 2001-2002NESARC








Age at first use, mean (SD), y 21.80 (0.67) 22.82 (0.39) .19
Period of heroin use
Past 12 mo only 2.02 (1.42) 3.23 (1.11)
.52Before past 12 mo only 90.73 (3.46) 86.17 (2.18)
Both 7.24 (3.27) 10.61 (1.84)
Period of heroin use disorder
Past 12 mo only 3.20 (2.25) 2.18 (1.08)
.47Before past 12 mo only 88.86 (5.20) 83.02 (3.38)
Both 7.94 (4.85) 14.80 (3.29)
Frequency of heroin use in lifetime
No. of times 1039.69 649.4 .05
1-5 times 38.97 (4.78) 31.97 (2.25)
<.001
6-100 times 9.91 (2.63) 24.29 (2.17)
>100 times 51.12 (5.00) 43.73 (2.45)
Frequency of use during heaviest period
Daily 36.35 (4.78) 30.04 (2.51)
.35Less than daily but monthly or more 22.61 (3.96) 29.02 (2.72)
Less than monthly 41.04 (4.90) 40.94 (2.72)
Frequency of use during heaviest period
Daily or near daily 39.11 (4.77) 37.01 (2.45)
.70
Less than daily or near daily 60.89 (4.77) 62.99 (2.45)
DSM-IV heroin use disorderb 63.35 (4.79) 42.69 (2.87) <.001
Heroin abuse 37.02 (4.67) 19.19 (2.34) .001
Heroin dependence 28.22 (3.95) 25.02 (2.20) .48
DSM-IV heroin abuse criteria
Role failure 43.03 (4.89) 21.40 (1.86) <.001
Physically hazardous use 47.46 (4.60) 31.79 (2.54) .005
Legal problems 23.58 (4.02) 12.99 (1.91) .02
Use persistence despite recurrent social problems 52.10 (5.03) 30.92 (2.50) <.001
DSM-IV heroin dependence criteria
Tolerance 35.96 (5.14) 31.42 (2.62) .43
Withdrawal 41.20 (4.98) 31.35 (2.55) .09
Larger amounts or longer 37.65 (5.04) 26.14 (2.20) .04
Persistent intention to quit 50.40 (5.06) 41.93 (2.66) .14
Time spent obtaining 42.05 (4.94) 32.93 (2.48) .10
Social or occupational dysfunction 34.22 (5.06) 25.10 (2.15) .10
Use persistence despite physical health problems due to heroin 38.48 (4.95) 29.38 (2.21) .10
DSM-IV heroin use disorder, No. of criteriab
0-1 39.83 (5.00) 55.16 (2.82)
.03
2-3 10.09 (2.67) 12.50 (1.91)
4-5 8.54 (2.67) 5.53 (1.34)
≥6 41.53 (5.09) 26.81 (2.28)
Driving under the influence of heroin, among heroin users 42.1 (4.7) 28.9 (2.2) .01
No history of any other drug use, among heroin users 0.0 (0.0) 2.1 (0.70) .003
NMPO use 68.9 (4.5) 76.0 (2.2) .15
Frequency of use during heaviest use period
Daily or near daily 21.93 (4.14) 33.54 (2.47)
.25
1-4 d/wk 22.32 (4.72) 16.38 (2.11)
1-3 times per mo 9.51 (2.88) 11.22 (1.70)
<1 time per mo 15.06 (2.97) 13.63 (1.79)
(continued)
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these populationswould likely increase the overall prevalence
of heroin use and use disorder.64,65 Because overall66 and
drug-related67,68 adult incarceration ratesdidnot increasedur-
ing thedecade between surveys, they should be comparable in
coveringheroinusers intheadultgeneralpopulation,andreports
oftimetrendsareunlikelytobebiased.TheAUDADIS-5interview-
ers were not clinicians, but a NESARC-III validation substudy
comparingAUDADIS and clinician diagnoses of lifetimeheroin
use disorder showed nearly identical prevalence and good
concordance.69 The NESARC-III response rate was acceptable
(60.1%)but lower thantheNESARCrate (81.0%).Weighting that
compensatedfornonresponse facilitatedcomparisonsbetween
the surveys. Surveyswith lower response ratesmaymissmore
substanceabusers,70potentially leading to lowerprevalence. If
thisoccurred inNESARC-III, theNESARCandNESARC-IIIdiffer-
ences reportedhereinmayunderestimate the true differences.
Inaddition,employersofNESARCandNESARC-III interviewers
were different (Census andWestat, respectively); whether this
differenceaffectedparticipant responses isunknown.However,
NESARCandNESARC-IIIwerepresented to respondentsasvol-
untary surveysconductedunder theauspicesof theUSgovern-
ment,possiblymitigatingthisdifference.Thevalidityofincreases
shown betweenNESARC andNESARC-III is supported by their







2 points, and we do not have information on fluctuations and
trends inheroinuseandrelateddisorderbetweenbothperiods.
We focusedonassociationswith lifetimeuse, lifetimedis-
order, andpatterns of lifetimedisorder across time,which are
important population parameters, particularly for very rare
conditions such as heroin outcomes in the general popula-
tion. For very rare conditions (eg, any heroin outcome in the
general population), examining lifetimecasesmaybe theonly
way todeterminedemographic andclinical correlates andpat-
terns of useduring the life course,which simply cannot be es-
timated from small numbers of survey participants with cur-
rent heroinuseor usedisorders. Furthermore, lifetimeheroin
use prevalence represents the burden on a population of a
highly riskybehavior forwhich sequelaeoftenpersist evenaf-
ter cessation of use of that particular drug.
Limitationsarebalancedbynumerousstrengths, including
use of AUDADIS in both surveys and assessment of more than
79000participants. Studydataprovideunique informationon
timetrendsduringaperiodwhenchangesassociatedwithheroin
usepatternsoccurred (eg, increase inwhiteusers, lowerpreva-
lenceofheroinusedisorder in recentyears).13,49 Study findings
provide context for further investigationof howdemographic,
clinical, andother risk factors forheroinuseandheroinusedis-
ordersmay have changed over time. Continuedmonitoring of
such time trends is an important public health priority.
Conclusions
The prevalences of heroin use and use disorder have in-
creased significantly in the US adult general population since
thebeginningof thismillennium.Ofnote, increaseshavebeen
greatest among men, white individuals, those with low in-
come and educational levels, and, for heroin use disorder,
younger individuals. To curb the heroin epidemic, particu-
larly among younger adults, collective prevention and inter-
vention efforts may be most effective.71 Promising examples
include expansion of access to medication-assisted treat-
ment (includingmethadonehydrochloride,buprenorphinehy-
drochloride, or injectable naltrexone hydrochloride), educa-
tionalprograms inschoolsandcommunitysettings,72overdose
prevention training in concert with comprehensive naloxone
hydrochloride distribution programs,73 and consistent use of
prescription drug monitoring programs that implement best
practices by prescribers.74,75 Efforts may be most efficient if
concentrated in states acutely affected by the opioid epi-
demic, as noted in President Obama’s Comprehensive Addic-
tion Recovery Act signed in July 2016.71 Although many par-
Table 3. Patterns of Heroin Use Among Lifetime Heroin Users in the the 2001-2002NESARC








Proportion of lifetime heroin users in categories of
frequency of NMPO use during heaviest use period
Daily or near daily 31.87 (5.64) 44.59 (3.01)
.25
1-4 d/wk 32.43 (6.26) 22.37 (2.76)
1-3 times per mo 13.81 (4.11) 14.91 (2.19)
<1 time per mo 21.88 (4.30) 18.12 (2.30)
Order of initiation of use
Before heroin 38.16 (5.05) 46.98 (2.50)
.20After heroin 12.14 (3.00) 15.73 (1.67)
Coincident with heroin or unknown 18.61 (4.01) 13.29 (1.90)
Use before heroin
Among nonwhite respondents 44.12 (7.60) 26.20 (3.95) .04
Among white respondents 35.83 (6.03) 52.83 (2.88) .01
Abbreviations: NESARC, National




a Prevalences and their SEs are
weighted and take into account the
complex survey designs of the
NESARC and the NESARC-III.
bDSM-IV heroin use disorder refers to
DSM-IV drug abuse or dependence.
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allels have been identified between increases in the PO
epidemic and in heroin use and its consequences, NMPO use
has decreased recently,whereas heroinuse and relateddisor-
ders continue to increase.17,49 Understanding these diverging
trends isan importantpublichealthchallenge thatmustbemet
to halt further increases.
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